Ivabradine, atrial fibrillation and stroke: a combined meta-analysis and FAERS disproportionality analysis

Alberto Spadotto^1,2Michele Fusaroli¹Maria Carelli²Elena Nardi²Martina Amadori¹Giulia Massaro¹Veronica De Angelis¹Milo Gatti¹Valerio Ciubine¹Emanuel Raschi¹Elisabetta Poluzzi¹Igor Diemberger^1*

• ¹University of Bologna, Bologna, Italy
• ²IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola, Bologna, Italy

Background: Previous RCTs and meta-analyses observed an increased occurrence of atrial fibrillation (AF) associated with ivabradine use. Nonetheless, these studies were not focused on AF diagnosis, and it remains unclear whether this observed increase is due to a direct effect of ivabradine or just an augmented AF detection. The latter mechanism could arise from a greater heart-rate differential between sinus rhythm and AF under ivabradine, potentially intensifying symptoms and prompting earlier clinical evaluation. If this hypothesis is true, an earlier diagnosis of AF, and subsequent earlier prophylaxis with anticoagulants, may result in a reduced incidence of ischemic cerebrovascular events. Methods: We conducted a meta-analysis of the existing literature (calculating the ratio between ischemic cerebrovascular events and AF) combined with a disproportionality analysis of individual case safety reports of suspected adverse drug reactions. In the disproportionality analysis, we also included beta-blockers as a comparator group, given their dromotropic effect. Results: From 555 studies screened in the meta-analysis, only three were considered eligible. The ratio between ischemic cerebrovascular events and AF with ivabradine was lower than with placebo (RR 0.74, 95% CI 0.62-0.89; p < 0.001). In the FAERS, AF was disproportionally reported with both ivabradine and beta-blockers (Information Component 0.84, 95% CI 0.43 – 1.14 and Information Component 0.53, 95% CI 0.44 – 0.60), while ischemic cerebrovascular events only with beta-blockers (Information Component 0.25, 95% CI 0.18 – 0.31). Conclusions: Our findings raise the hypothesis that ivabradine facilitates an increased diagnosis rather than playing a direct role in causing AF. Prospective studies with continuous ECG monitoring and standardized endpoints are needed to clarify the temporal and mechanistic relationship between ivabradine, AF recognition, and cerebrovascular risk.